Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease.

Feng W, Gao C, Bi Y, Wu M, Li P, Shen S, Chen W, Yin T, Zhu D

Journal of diabetes29 May 2017Cited by 135 (Europe PMC)

PMID28332301DOI10.1111/1753-0407.12555PepBankPUB-28332301

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, HbA1c fell after 24 weeks of treatment in all three groups, including liraglutide.
In plain wordsIn adults with type 2 diabetes and fatty liver, HbA1c fell after 24 weeks in all three treatment groups, including liraglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction from baseline
Study
n = 87
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both HbA1c levels and IHF content were reduced after treatment in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
Report a problemFND-2833230101
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, intrahepatic fat content fell after 24 weeks of treatment in all three groups, including liraglutide.
In plain wordsIn adults with type 2 diabetes and fatty liver, liver fat fell after 24 weeks in all three treatment groups, including liraglutide.
Peptide
Liraglutide
Outcome
DecreaseIntrahepatic fat content reduction
Study
n = 87
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Both HbA1c levels and IHF content were reduced after treatment in all three groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
Report a problemFND-2833230102
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, liraglutide improved liver function over 24 weeks.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide improved liver function over 24 weeks.
Peptide
Liraglutide
Outcome
Not applicableLiver function
Study
n: not reported in source
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin treatments reduced weight and improved liver function.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
Report a problemFND-2833230106
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, HbA1c levels were lower with liraglutide than with gliclazide.
In plain wordsIn adults with type 2 diabetes and fatty liver, HbA1c was lower with liraglutide than with gliclazide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c, liraglutide versus gliclazide
Study
n: not reported in source
Comparator
Gliclazide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
HbA1c levels were lower in the liraglutide- and metformin-treated groups than in the gliclazide-treated group
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
Report a problemFND-2833230103
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, reductions in intrahepatic fat content were greater with liraglutide than with gliclazide.
In plain wordsIn adults with type 2 diabetes and fatty liver, liver fat fell more with liraglutide than with gliclazide.
Peptide
Liraglutide
Outcome
DecreaseIntrahepatic fat reduction, liraglutide versus gliclazide
Study
n: not reported in source
Comparator
Gliclazide
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
reductions in IHF content were greater with liraglutide than with gliclazide.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
Report a problemFND-2833230104
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and NAFLD, liraglutide reduced body weight over 24 weeks.
In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide reduced body weight over 24 weeks.
Peptide
Liraglutide
Outcome
DecreaseWeight reduction
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
Liraglutide and metformin treatments reduced weight and improved liver function.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
Report a problemFND-2833230105

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

07HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes and NAFLD, changes in intrahepatic fat content correlated positively with reductions in serum ALT, triglycerides and weight across all treatment groups.
In plain wordsIn adults with type 2 diabetes and fatty liver, larger falls in liver fat went with larger falls in liver enzyme, blood fats and weight.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of intrahepatic fat change with ALT, triglyceride and weight reductions
Study
n = 87
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Changes in IHF content were positively correlated with reductions in serum alanine aminotransferase and triglyceride levels, as well as weight.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2833230107
08HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In adults with type 2 diabetes and NAFLD, intrahepatic fat reductions at 24 weeks were greater in subjects with weight loss of 5% or more, a waistline change of 0 cm or less, HbA1c reductions of 2.5% or more, and HbA1c below 6.5%.
In plain wordsIn adults with type 2 diabetes and fatty liver, liver fat fell more in people who lost weight or waist size.
Peptide
Liraglutide
Outcome
Not applicableIntrahepatic fat reduction by subgroup at 24 weeks
Study
n = 87
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
At 24 weeks, reductions in IHF content were greater in subjects with weight loss ≥5%, changes in waistline ≤0 cm (including decreases in waistline), HbA1c reductions ≥2.5%, and HbA1c levels <6.5%.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighty-seven subjects were randomized to receive liraglutide, metformin, or gliclazide for 24 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2833230108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.